MedPath

Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk

Not Applicable
Terminated
Conditions
Ovarian Cancer
Registration Number
NCT00017134
Lead Sponsor
Gynecologic Oncology Group
Brief Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known whether fenretinide given before surgery is more effective in preventing ovarian cancer than surgery alone.

PURPOSE: Randomized clinical trial to compare the effectiveness of fenretinide followed by surgery with that of surgery alone in preventing ovarian cancer in patients who are at increased risk.

Detailed Description

OBJECTIVES:

* Compare the frequency of histopathology markers or precursor lesions of the ovaries, including surface papillomatosis, invaginations, pseudostratification, and inclusion cysts, removed from patients at increased risk for ovarian cancer between those receiving fenretinide vs those undergoing immediate oophorectomy.

* Determine the relative abundance of markers of cell proliferation and apoptosis in cancer-prone ovaries of patients treated with fenretinide.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 arms.

* Arm I: Patients undergo prophylactic oophorectomy.

* Arm II: Patients receive oral fenretinide once daily for 27 days every 30 days for 6-8 weeks. Treatment continues in the absence of unacceptable toxicity or diagnosis of malignancy. After completion of fenretinide, patients undergo prophylactic oophorectomy.

Patients are followed every 3 months for 2 years and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 71 patients will be accrued for this study within 2 years.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
71
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (35)

CCOP - Metro-Minnesota

🇺🇸

Saint Louis Park, Minnesota, United States

St. John's Regional Health Center

🇺🇸

Springfield, Missouri, United States

Hulston Cancer Center at Cox Medical Center South

🇺🇸

Springfield, Missouri, United States

St. Vincent Indianapolis Hospital

🇺🇸

Indianapolis, Indiana, United States

Charles M. Barrett Cancer Center at University Hospital

🇺🇸

Cincinnati, Ohio, United States

Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital

🇺🇸

Fort Lauderdale, Florida, United States

Fletcher Allen Health Care - University Health Center Campus

🇺🇸

Burlington, Vermont, United States

Markey Cancer Center at University of Kentucky Chandler Medical Center

🇺🇸

Lexington, Kentucky, United States

Holden Comprehensive Cancer Center at University of Iowa

🇺🇸

Iowa City, Iowa, United States

Hillcrest Cancer Center at Hillcrest Hospital

🇺🇸

Mayfield Heights, Ohio, United States

Jonsson Comprehensive Cancer Center at UCLA

🇺🇸

Los Angeles, California, United States

Memorial Hospital of South Bend

🇺🇸

South Bend, Indiana, United States

University of Minnesota Medical Center & Children's Hospital - Fairview

🇺🇸

Minneapolis, Minnesota, United States

Siteman Cancer Center at Barnes-Jewish Hospital

🇺🇸

St Louis, Missouri, United States

Helen and Harry Gray Cancer Center at Hartford Hospital

🇺🇸

Hartford, Connecticut, United States

George Bray Cancer Center at New Britain General Hospital

🇺🇸

New Britain, Connecticut, United States

Evanston Northwestern Healthcare - Evanston Hospital

🇺🇸

Evanston, Illinois, United States

William Beaumont Hospital - Royal Oak Campus

🇺🇸

Royal Oak, Michigan, United States

CCOP - Cancer Research for the Ozarks

🇺🇸

Springfield, Missouri, United States

Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest

🇺🇸

Allentown, Pennsylvania, United States

University of Texas Medical Branch

🇺🇸

Galveston, Texas, United States

Oklahoma University Medical Center

🇺🇸

Oklahoma City, Oklahoma, United States

Colorado Gynecologic Oncology Group P.C.

🇺🇸

Aurora, Colorado, United States

Oregon Health & Science University Cancer Institute

🇺🇸

Portland, Oregon, United States

Cancer Institute of New Jersey at Cooper - Voorhees

🇺🇸

Voorhees, New Jersey, United States

Roswell Park Cancer Institute

🇺🇸

Buffalo, New York, United States

CCOP - Northern New Jersey

🇺🇸

Hackensack, New Jersey, United States

Mount Sinai Medical Center

🇺🇸

New York, New York, United States

Blumenthal Cancer Center at Carolinas Medical Center

🇺🇸

Charlotte, North Carolina, United States

McDowell Cancer Center at Akron General Medical Center

🇺🇸

Akron, Ohio, United States

Riverside Methodist Hospital Cancer Care

🇺🇸

Columbus, Ohio, United States

Mount Carmel Health - West Hospital

🇺🇸

Columbus, Ohio, United States

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

🇺🇸

Chapel Hill, North Carolina, United States

Virginia Commonwealth University Massey Cancer Center

🇺🇸

Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath